source
- Genetix Biotherapeutics reports $327M YTD sales and projects $500M full-year revenue, marking profitabilityGenetix Biotherapeutics, the former bluebird bio, announced that it has become profitable, reporting $327 million in U.S. net sales year‑to‑date and forecasting total 2026 sales of about $500 milli…
- FDA flags VEGF safety concern in Summit Therapeutics' rejected bispecific cancer drug ivonescimabThe U.S. Food and Drug Administration identified a potential safety issue while reviewing ivonescimab, a bispecific cancer therapy being developed by Summit Therapeutics and Akeso. The agency’s co…